Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Gilead and Terray Partner for Multi-Target Discovery Of Small Molecule Therapies
Details : The strategic collaboration aims to leverage Terray's tNova platform to discover and develop novel small-molecule therapies targeting multiple targets selected by Gilead.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Recipient : Odyssey Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Odyssey And Terray Therapeutics Partner on Transcription Factor Therapies
Details : The companies will work to develop first-in-class therapeutic candidates for high-interest targets with potential application across immune and inflammatory diseases.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Recipient : Odyssey Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Bedford Ridge Capital
Deal Size : $120.0 million
Deal Type : Series B Financing
Terray Therapeutics Closes $120M Series B for Small Molecule Therapeutics
Details : The funding will progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova, which it uses to power both internal and partnered programs.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
October 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Bedford Ridge Capital
Deal Size : $120.0 million
Deal Type : Series B Financing